A surreal illustration depicting the interconnectedness of heart and kidney health, symbolizing the increased risks associated with atrial fibrillation and declining kidney function.

Kidney Function's Hidden Link to Heart Health: What You Need to Know

Theo Raines monogram
Theo Raines in Health & Wellness November 2026 • 4 min read.

"New research reveals how declining kidney function significantly raises the risk of blood clots and bleeding in atrial fibrillation patients, challenging common treatment strategies."


Atrial fibrillation (AFib), a common heart rhythm disorder, affects millions worldwide. While the primary concern is stroke prevention, the delicate balance between preventing blood clots and avoiding excessive bleeding requires careful consideration, especially when kidney function is compromised.

A groundbreaking study, the UMBRIA-FA study, sheds light on the intricate relationship between kidney function, stroke/thromboembolism risk, and bleeding risk in patients with AFib. This research challenges conventional wisdom and highlights the need for personalized treatment strategies based on a patient's kidney health.

This article delves into the key findings of the UMBRIA-FA study, explaining how declining kidney function can significantly impact the risk of adverse events in AFib patients and what this means for treatment decisions. We'll explore the implications for both patients and healthcare providers, offering insights into a more tailored approach to managing AFib in the context of kidney disease.

AI Search Multiple angles on this topic

Atrial Fibrillation Burden in CKD

A 2025 study found significant differences in atrial fibrillation (AF) burden between 2011 and 2022 across kidney function groups. People with chronic kidney disease (CKD), particularly those receiving dialysis, had higher AF incidence and prevalence than people with preserved kidney function. These findings describe differences in burden across kidney function groups, rather than a specific overall prevalence figure.

Anticoagulation in Kidney Failure

Oral anticoagulants are established for preventing thromboembolism in atrial fibrillation, but their use in people on long-term dialysis remains debatable. Managing AF in kidney failure is difficult because stroke risk is high while bleeding risk is also high, and clinicians have limited treatment options to improve outcomes. The sources therefore describe a tension between preventing thromboembolism and avoiding bleeding in this population.

The Alarming Connection: Declining Kidney Function, Increased Risks

A surreal illustration depicting the interconnectedness of heart and kidney health, symbolizing the increased risks associated with atrial fibrillation and declining kidney function.

The UMBRIA-FA study included a cohort of 1,847 patients with AFib, carefully examining the link between their kidney function (measured by estimated glomerular filtration rate or eGFR) and the occurrence of stroke, thromboembolism, and bleeding events. The study revealed a clear and concerning trend: as kidney function declined, the risk of both stroke/thromboembolism and bleeding significantly increased.

Specifically, the study found that patients with lower eGFRs had substantially higher CHA2DS2VASc scores (a measure of stroke risk) and HAS-BLED scores (a measure of bleeding risk). This indicates that individuals with impaired kidney function are inherently more vulnerable to both types of complications associated with AFib.

Key findings of the UMBRIA-FA study:
  • A significant association between declining kidney function and increased risk of stroke/thromboembolism and bleeding in patients with atrial fibrillation.
  • Patients with lower eGFRs (indicating poorer kidney function) had higher CHA2DS2VASc and HAS-BLED scores, suggesting a greater overall risk profile.
  • The use of VKA (vitamin K antagonists like warfarin) was more prevalent in patients with significantly reduced kidney function (eGFR <30 ml/min/1.73m2).
  • Conversely, the prescription of newer oral anticoagulants (NVKA) was less common in patients with severely impaired kidney function.
AI Search Multiple angles on this topic

Evidence on Anticoagulant Choice

A meta-analysis of randomized trials compared direct oral anticoagulants (DOACs) with vitamin K antagonists in people with AF and end-stage kidney disease receiving hemodialysis. Its background notes that thromboembolic risk rises as glomerular filtration rate falls, while end-stage kidney disease carries pronounced bleeding risk and the possibility of cumulative drug effects. The supplied material explains why anticoagulant choice matters, but does not report which treatment performed better.

Limits of Available Evidence

In the prospective GARFIELD-AF registry, event counts were too low to compare the impact of CKD severity on outcomes by region using adjusted analyses. A separate population-based study of older adults with AF starting warfarin included few participants with kidney function below 30 mL/min/1.73 m² compared with those with normal or moderate function. The authors said this limited subgroup size affected the stability of their point estimates.

Balancing Stroke, Bleeding, and Kidney Risks

In kidney failure, AF management is challenging because stroke risk is disproportionately high, bleeding risk is also high, and treatment options are limited. Separately, real-world data in AF patients treated with DOACs found an eGFR reduction of at least 30% in one in four patients at two years. The report says the degree of kidney function decline can be influenced by the type of DOAC administered.

This raises critical questions about the appropriateness of current treatment guidelines, which may not adequately account for the heightened risks associated with reduced kidney function. The study suggests a potential over-reliance on VKAs in patients with poor kidney function, despite the availability of newer, potentially safer alternatives.

Rethinking Treatment Strategies: A Call for Personalized Care

The UMBRIA-FA study underscores the critical need for a more individualized approach to managing AFib, particularly in patients with compromised kidney function. Simply put, a one-size-fits-all treatment strategy may not be sufficient to address the complex interplay of risks and benefits in this vulnerable population.

AI Search Multiple angles on this topic

AF and Clinical Complexity

A May 5, 2026 article on cardio-kidney-metabolic phenotypes describes atrial fibrillation as a major challenge in contemporary cardiology. It points to AF’s high prevalence and the clinical complexity of the patients in whom it occurs. The supplied summary does not provide specific phenotype statistics or outcome estimates.

The study's findings advocate for a more cautious and nuanced approach to anticoagulation therapy in patients with AFib and kidney disease. This includes a thorough assessment of kidney function, careful consideration of the individual patient's risk profile (including both stroke and bleeding risks), and a thoughtful discussion about the potential benefits and risks of different anticoagulation options.

Ultimately, the goal is to optimize treatment strategies to minimize the risk of adverse events and improve outcomes for all patients with AFib, regardless of their kidney function. Further research is needed to refine these strategies and develop evidence-based guidelines for managing AFib in the context of chronic kidney disease.

Reported rates across kidney and treatment groups

  • 48.5 %Among people with atrial fibrillation receiving hemodialysis and oral anticoagulation, the rate of death or clinically relevant bleeding was 48.5%.[1]
  • 26.8 %In the same setting, the rate of stroke, myocardial infarction, systemic or pulmonary embolism, or death was 26.8%.[1]
  • OR 0.78 (95% CI, 0.67–0.91) odds ratioFor atrial fibrillation with mild renal insufficiency, NOAC use was associated with lower stroke odds than the comparator treatment (OR 0.78; 95% CI, 0.67–0.91).[2]
  • 16%–21%; 15%–40% %Reported atrial fibrillation prevalence ranged from 16% to 21% in CKD patients not dependent on dialysis, and from 15% to 40% in patients on dialysis.[3]
  • 1.46; 1.49; 9.29; 1.57 adjusted hazard ratioIn a group whose renal function worsened, adjusted hazard ratios were 1.46 for major bleeding, 1.49 for end-stage renal disease, 9.29 for all-cause death, and 1.57 for the composite outcome.[4]
  • 17%; 50.9% %CKD-EPI eGFR estimates overestimated values relative to the Cockcroft–Gault equation in 17% of patients; among patients aged at least 75 years and weighing under 50 kg, the corresponding figure was 50.9%.[5]
  • nearly 10 %CKD was described as affecting nearly 10% of the adult population.[2]

What the comparisons can and cannot establish

The hemodialysis figures describe substantial event burdens in people already receiving anticoagulation, but the overlapping event composites do not establish that one outcome is more likely than another.[1]

The apixaban–warfarin comparison does not establish a reliable bleeding difference: the trial report says it lacked adequate power to draw a conclusion on that outcome. The reported stroke comparison is a separate endpoint, not proof that either treatment is superior overall.[6]

How other evidence frames kidney measures and anticoagulation

CKD and atrial fibrillation share risk factors and may also be linked through systemic processes such as inflammation, oxidative stress, or fibrosis; this makes the relationship more complex than a single kidney-function measure alone.[3] [7]

A meta-analysis background notes that reduced filtration can coincide with thromboembolic risk, while kidney failure may also allow drug effects to accumulate. This frames anticoagulant choice as a balance of risks and drug handling, rather than a simple comparison of event rates.[8]

DOACs are cleared through the kidneys to varying degrees, which has implications for dose adjustment as kidney function changes.[4]

Population-based research on kidney function and atrial fibrillation has reported conflicting results; some earlier work also relied on creatinine alone to estimate filtration.[7]

Questions the evidence leaves open

  • How would the stroke findings from analyses without medication information look if anticoagulant use were accounted for?[9]
  • Would a better-powered comparison clarify whether bleeding outcomes differ between apixaban and warfarin in hemodialysis patients?[6]
  • How much do conclusions about kidney function and atrial fibrillation depend on the equation used to estimate filtration, given the reported differences between formulas?[5] [7]

Sources

  1. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study (pmc.ncbi.nlm.nih.gov)
  2. The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients (pmc.ncbi.nlm.nih.gov)
  3. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference (pmc.ncbi.nlm.nih.gov)
  4. Association between changes in renal function and clinical outcomes in anticoagulated atrial fibrillation patients with marginal renal function. A nationwide observational cohort study (pmc.ncbi.nlm.nih.gov)
  5. Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation (pmc.ncbi.nlm.nih.gov)
  6. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. (pubmed.ncbi.nlm.nih.gov)
  7. Bidirectional Association Between Kidney Function and Atrial Fibrillation: A Population‐Based Cohort Study (pmc.ncbi.nlm.nih.gov)
  8. Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists (pmc.ncbi.nlm.nih.gov)
  9. The Risk of Stroke and Stroke Type in Patients With Atrial Fibrillation and Chronic Kidney Disease. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Atrial fibrillation and why is it a concern?

Atrial fibrillation (AFib) is a common heart rhythm disorder affecting millions worldwide. It's a condition where the heart beats irregularly, increasing the risk of stroke. The primary concern related to AFib is stroke prevention, requiring a delicate balance between preventing blood clots and avoiding excessive bleeding. The UMBRIA-FA study focuses on patients with AFib, examining the impact of kidney function on the risk of stroke/thromboembolism and bleeding events.

2

What is the UMBRIA-FA study?

The UMBRIA-FA study is a groundbreaking research effort that investigated the relationship between kidney function and the risk of stroke, thromboembolism, and bleeding in Atrial fibrillation (AFib) patients. It included a cohort of 1,847 AFib patients, carefully examining the link between their kidney function (measured by estimated glomerular filtration rate or eGFR) and the occurrence of these adverse events. The study aimed to challenge current treatment strategies, highlighting the need for personalized treatment strategies based on a patient's kidney health.

3

How does declining kidney function impact the risks associated with Atrial fibrillation?

Declining kidney function significantly increases the risk of both stroke/thromboembolism and bleeding in individuals with Atrial fibrillation (AFib). The UMBRIA-FA study revealed that patients with lower eGFRs (indicating poorer kidney function) had higher CHA2DS2VASc scores (a measure of stroke risk) and HAS-BLED scores (a measure of bleeding risk). The use of VKA (vitamin K antagonists like warfarin) was more prevalent in patients with significantly reduced kidney function. This suggests those with impaired kidney function are more vulnerable to complications associated with AFib and current treatment guidelines might not adequately account for these heightened risks.

4

What is the significance of the CHA2DS2VASc score?

The CHA2DS2VASc score measures the risk of stroke in patients with Atrial fibrillation (AFib). The study found that patients with lower eGFRs (poorer kidney function) had higher CHA2DS2VASc scores. This means that as kidney function declines, the likelihood of stroke increases, underscoring the interconnectedness of kidney and heart health in AFib patients. Healthcare providers use the CHA2DS2VASc score, alongside other factors, to determine the most appropriate treatment strategy for stroke prevention.

5

Why might current treatment approaches need to be rethought?

Current treatment strategies may need to be re-evaluated because the UMBRIA-FA study suggests a potential over-reliance on VKAs (vitamin K antagonists like warfarin) in patients with poor kidney function. The study indicates that individuals with declining kidney function face heightened risks of both stroke/thromboembolism and bleeding, making the standard one-size-fits-all treatment guidelines inadequate. The prescription of newer oral anticoagulants (NVKA) was less common in patients with severely impaired kidney function. Healthcare providers need to adopt a more individualized approach, taking into account a patient's kidney health when making treatment decisions for AFib.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.